CEL-SCI CORPORATION (CVM) Scorecard
- 2026-Q2: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth No data; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth No data; EPS growth Lose.
14/53
1.3 / 5 stars
All 53 Win/Lose results and 67 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 1 wins, 7 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseCVM / S&P -67.60% / 15.20% |
No dataCVM / S&P / 15.00% |
LoseCVM / S&P -82.03% / 50.40% |
| 2026-Q10/2 |
LoseCVM / S&P -38.97% / -4.33% |
No dataCVM / S&P / 11.30% |
LoseCVM / S&P -78.98% / 27.70% |
| 2025-Q40/2 |
LoseCVM / S&P -42.83% / 2.65% |
No dataCVM / S&P / 9.00% |
LoseCVM / S&P -58.53% / 13.40% |
| 2025-Q31/2 |
WinCVM / S&P 301.75% / 8.12% |
No dataCVM / S&P / 4.61% |
LoseCVM / S&P -5.37% / 13.45% |
| 2025-Q20/1 |
LoseCVM / S&P -66.81% / 10.94% |
No dataCVM / S&P / 4.83% |
No dataCVM / S&P / 10.63% |
| 2025-Q10/1 |
LoseCVM / S&P -42.50% / -4.27% |
No dataCVM / S&P / 4.98% |
No dataCVM / S&P / 10.57% |
| 2024-Q40/1 |
LoseCVM / S&P -62.26% / 2.41% |
No dataCVM / S&P / 5.25% |
No dataCVM / S&P / 6.15% |
| 2024-Q30/1 |
LoseCVM / S&P -8.62% / 5.89% |
No dataCVM / S&P / 5.89% |
No dataCVM / S&P / 6.11% |
| 2024-Q20/1 |
LoseCVM / S&P -39.27% / 4.28% |
No dataCVM / S&P / 5.38% |
No dataCVM / S&P / 5.12% |
| 2024-Q10/1 |
LoseCVM / S&P -29.78% / 10.56% |
No dataCVM / S&P / 5.71% |
No dataCVM / S&P / 5.59% |
| 2023-Q41/1 |
WinCVM / S&P 117.60% / 11.69% |
No dataCVM / S&P / 6.81% |
No dataCVM / S&P / 7.78% |
| 2023-Q30/1 |
LoseCVM / S&P -48.13% / -3.27% |
No dataCVM / S&P / 7.52% |
No dataCVM / S&P / -5.03% |
| 2023-Q20/1 |
LoseCVM / S&P 3.88% / 8.74% |
No dataCVM / S&P / 9.50% |
No dataCVM / S&P / -8.57% |
| 2023-Q10/1 |
LoseCVM / S&P -1.28% / 7.50% |
No dataCVM / S&P / 10.77% |
No dataCVM / S&P / -15.69% |
| 2022-Q41/2 |
LoseCVM / S&P -23.95% / 7.56% |
No dataCVM / S&P / 11.88% |
WinCVM / S&P -4.49% / -17.99% |
| 2022-Q30/2 |
LoseCVM / S&P -31.33% / -4.88% |
No dataCVM / S&P / 13.47% |
LoseCVM / S&P -3.33% / -1.41% |
| 2022-Q21/2 |
WinCVM / S&P 14.50% / -16.10% |
No dataCVM / S&P / 13.71% |
LoseCVM / S&P -5.75% / 11.04% |
| 2022-Q10/2 |
LoseCVM / S&P -44.65% / -4.60% |
No dataCVM / S&P / 15.97% |
LoseCVM / S&P -5.62% / 42.23% |
| 2021-Q40/2 |
LoseCVM / S&P -35.40% / 11.03% |
No dataCVM / S&P / 15.00% |
LoseCVM / S&P 3.49% / 96.40% |
| 2021-Q31/2 |
WinCVM / S&P 26.61% / 0.58% |
No dataCVM / S&P / 10.77% |
LoseCVM / S&P 11.11% / 69.42% |
| 2021-Q20/1 |
LoseCVM / S&P -42.93% / 8.55% |
No dataCVM / S&P / 6.58% |
No dataCVM / S&P / 51.81% |
| 2021-Q11/1 |
WinCVM / S&P 30.45% / 6.17% |
No dataCVM / S&P / -1.06% |
No dataCVM / S&P / 7.39% |
| 2020-Q40/1 |
LoseCVM / S&P -8.55% / 12.15% |
No dataCVM / S&P / -3.72% |
No dataCVM / S&P / -33.42% |
| 2020-Q30/1 |
LoseCVM / S&P -14.54% / 8.93% |
No dataCVM / S&P / -2.04% |
No dataCVM / S&P / -27.10% |
| 2020-Q21/1 |
WinCVM / S&P 29.29% / 20.54% |
No dataCVM / S&P / -0.46% |
No dataCVM / S&P / -27.11% |
| 2020-Q11/1 |
WinCVM / S&P 26.12% / -19.60% |
No dataCVM / S&P / 3.47% |
No dataCVM / S&P / -14.75% |
| 2019-Q40/1 |
LoseCVM / S&P 2.35% / 9.07% |
No dataCVM / S&P / 5.36% |
No dataCVM / S&P / 2.99% |
| 2019-Q31/1 |
WinCVM / S&P 6.68% / 1.70% |
No dataCVM / S&P / 5.02% |
No dataCVM / S&P / 0.21% |
| 2019-Q21/1 |
WinCVM / S&P 136.72% / 4.30% |
No dataCVM / S&P / 6.64% |
No dataCVM / S&P / 8.65% |
| 2019-Q11/2 |
WinCVM / S&P 23.34% / 13.65% |
No dataCVM / S&P / 8.12% |
LoseCVM / S&P -35.05% / 14.29% |
| 2018-Q40/2 |
LoseCVM / S&P -29.14% / -13.52% |
No dataCVM / S&P / 9.05% |
LoseCVM / S&P -51.44% / 18.23% |
| 2018-Q31/2 |
WinCVM / S&P 340.22% / 7.71% |
No dataCVM / S&P / 10.21% |
LoseCVM / S&P -1.55% / 19.06% |
| 2018-Q20/1 |
LoseCVM / S&P -34.75% / 3.43% |
No dataCVM / S&P / 9.03% |
No dataCVM / S&P / 14.46% |
| 2018-Q10/1 |
LoseCVM / S&P -25.40% / -0.76% |
No dataCVM / S&P / 7.68% |
No dataCVM / S&P / 12.46% |
| 2017-Q41/1 |
WinCVM / S&P 13.86% / 6.64% |
No dataCVM / S&P / 7.03% |
No dataCVM / S&P / 13.82% |
| 2017-Q30/1 |
LoseCVM / S&P -25.56% / 4.48% |
No dataCVM / S&P / 5.68% |
No dataCVM / S&P / 17.57% |
| 2017-Q20/1 |
LoseCVM / S&P -0.89% / 3.09% |
No dataCVM / S&P / 4.83% |
No dataCVM / S&P / 17.74% |
| 2017-Q11/1 |
WinCVM / S&P 28.57% / 6.07% |
No dataCVM / S&P / 3.67% |
No dataCVM / S&P / 13.32% |
| 2016-Q40/1 |
LoseCVM / S&P -77.42% / 3.82% |
No dataCVM / S&P / 2.09% |
No dataCVM / S&P / 7.05% |
| 2016-Q30/1 |
LoseCVM / S&P -32.61% / 3.85% |
No dataCVM / S&P / 0.20% |
No dataCVM / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CVM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -84.66% | 20.78% |
| Annualized return | -84.66% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CVM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.53% | 83.14% |
| Annualized return | -65.78% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CVM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.56% | 319.30% |
| Annualized return | -41.82% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |